Biolex Therapeutics
Harnessing aquatic innovation for potent protein therapeutics and advanced Hepatitis C treatments.
Harnessing aquatic innovation for potent protein therapeutics and advanced Hepatitis C treatments.
Biolex Therapeutics is a clinical-stage biopharmaceutical company that leverages their innovative LEX SystemSM to develop therapeutic proteins and monoclonal antibodies, with a focus on addressing challenging-to-produce biologics. The company harnesses the aquatic plant Lemna through genetic modification to enable the production of biologic product candidates. Established in 1997, Biolex's primary offering targets the treatment of Hepatitis C. The company recently secured a $2.36M Debt Financing investment on 19 December 2011, signaling investor confidence in their pioneering approach to biotechnology and healthcare.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $2.36M | - | 19 Dec 2011 | |
| Debt Financing | $5.90M | - | 09 Jun 2011 | |
| Series D | $20.00M | - | 29 Oct 2010 | |
| Debt Financing | $10.00M | - | 23 Feb 2010 | |
| Series D | $60.00M | 10 |
|
06 Oct 2008 |
No recent news or press coverage available for Biolex Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
